United States· US:50090-4383_706b12b0-f37f-4e9c-9776-038d78f4b9de

Tradjenta

A linagliptin product containing linagliptin, registered in United States by A-S Medication Solutions. The same ATC class is registered in 17 of our 19 countries.

ATC A10BH05US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedTradjentaATCA10BH05REGISTER NO.US:50090-4383_706b12b…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Linagliptin is registered in 17 of 19 countries.

Countries holding a registration under ATC A10BH05 (linagliptin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Linagliptin · ATC A10BH05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of linagliptin costs, country by country.

Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Linagliptin · price per daily dose (5 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.52
  • CH Switzerland$2.05
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
LINAGLIPTIN
Manufacturer
A-S Medication Solutions
Country
United States (US)
ATC code
A10BH05
ATC class
Linagliptin
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    50090-4383-0
  • ndc11
    5009043830
    90 TABLET, FILM COATED in 1 BOTTLE (50090-4383-0)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

373 interactions on record for linagliptin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Linagliptin · interactions on record

373 records

  • 3 severe
  • 330 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Linagliptin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All linagliptin products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Ilinpru, Liamell
  • Belgium · Linagliptin Eg, Linagliptin Eg (Eurogenerics) Nv
  • Bulgaria · Linagliptin Accord, Глунава
  • Cyprus · Glunava, Linagliptin Accord
  • Czechia · Glunava, Jeligo
  • Germany · Linagliptin Abdi
  • Denmark · Linagliptin "pharmapath", Linagliptin Accord
  • Estonia · Glunava, Linagliptin Accord
  • Spain · Donumid, Ilinpru
  • Finland · Linagliptin Accord, Linagliptin Advanz Pharma
  • France · Linagliptine Zentiva
  • United Kingdom (Northern Ireland) · Linagliptin, Linagliptin Altair Science
  • Greece · Bottiar, Drojarto
  • Croatia · Larida, Liglinra
  • Hungary · Ilinpru, Jeligo
  • Ireland · Linagliptin Accord, Linagliptin Clonmel
  • Iceland · Linagliptin Krka, Linagliptin Stada
  • Italy · Linagliptin Abdi, Linagliptin Aurobindo
  • Liechtenstein · Trajenta
  • Lithuania · Bottiar, Jeligo
  • Luxembourg · Linagliptin Eg
  • Latvia · Linagliptin Accord, Linagliptin Olpha
  • Malta · Liamell, Linagliptin
  • Netherlands · Linagliptin Viatris, Linagliptin Vivanta
  • Norway · Linagliptin Accord, Linagliptin Krka
  • Poland · Jeligo, Larida
  • Portugal · Enanta, Larida
  • Romania · Jeligo, Linagliptin Medochemie
  • Sweden · Liglinra, Linagliptin Accord
  • Slovenia · Liglipex, Linagliptin Krka
  • Slovakia · Glunava, Ilinpru

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dda055be-f73e-44c9-94f8-506dd9834e59
GET /v1/drugs/dda055be-f73e-44c9-94f8-506dd9834e59?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "5",
  "substance": "LINAGLIPTIN",
  "productndc": "50090-4383",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA201280",
  "marketing_category": "NDA"
}

See everything about linagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.